Spherix Global Insights

June 24, 2022

Lilly and Boehringer’s Jardiance Poised for Challenge to AZ’s Market Leader Farxiga in Chronic Kidney Disease: Spherix

Life science launch analyst Spherix reached that conclusion after analyzing the results of two surveys—one of 104 U.S. nephrologists and another of 330 nephrologists, cardiologists, endocrinologists and primary care doctors.

While Farxiga is currently the SGLT2 inhibitor of choice among nephrologists, Spherix found Jardiance’s early trial stop has made an impression: Nearly 70% of the kidney specialists surveyed in April expect to write more prescriptions for the drug in the next six months in response to the news, with 14% of those expecting a “significant” increase.